《公司業績》石四藥(02005.HK)首九月未經審核純利按年增長65.2%
石四藥集團(02005.HK)公布,首九個月未經審核經營業績,錄得營業額按年增長24.2%,至約48.73億元,主要由於銷售費用率有所下降。純利按年增加65.2%至約8.36億元,主要由於期內原料藥之未經審核營業額大幅增加198.8%,當中咖啡因系列產品的未經審核營業額大幅增加277.8%,對集團未經審核純利作出更大貢獻。
期內毛利約27.42億元,按年增加16.9%;毛利率約56.3%,按年跌3.5個百分點,主要原因是原料藥所佔集團未經審核營業額的比例有所提升,而原料藥的毛利率低於藥物製劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.